Glutamate is an amino acid in all dietary protein, sold as the savoury seasoning monosodium glutamate. Its best-supported effect is on taste: it makes food with less salt taste right, so salt can be cut without the food tasting flat. Smaller findings point to faster stomach emptying and a gentler blood-sugar rise. Large amounts in liquid without food produce headache in some people; heavy habitual use tracks rising blood pressure. (Full Review)

Protocol

Standard culinary regimen

0.3% by weight

In soups and broths, and 0.3–0.8 g per savoury serving, substituting for part of the added salt rather than supplementing it

Single versus split dosing

Split across meals

A single large dose is the exposure pattern that produces symptoms; documented benefits require the compound alongside the food being eaten

Pre-existing conditions

1–2.7 g daily

The level at which deliberate supplementation has been trialled, in delayed gastric emptying, chemotherapy-induced taste loss, and poor appetite with weight loss

Time to effect

Taste effect

Immediate

The saltiness and palatability gain that allows salt to be displaced is present at the first meal

Gastric emptying & post-meal glucose

Within the same meal

Both effects are meal-linked, which is why doses are distributed across the main meals

Taste preference adaptation to lower salt

2–4 weeks

Any blood-pressure consequence of the reduced sodium follows over weeks to months

Benefits

Medium: Sodium reduction at preserved palatability; lower post-meal glucose and reduced hyperglycemia risk; accelerated gastric emptying of protein-rich meals; preserved taste function during chemotherapy

Low: Greater food and nutrient intake in undernourished older adults; higher hemoglobin and faster recovery from anemia; improved exercise tolerance in stable angina; increased salivary flow and relief of age-related umami taste loss; enhanced post-meal satiety

Speculative: Gut mucosal fuel and glutathione precursor supply

Contraindications

Reproducible, blinded symptom reaction at or below 2.5 g without food

Migraine with an established, diary-documented dietary trigger pattern

Myofascial temporomandibular disorder or fibromyalgia with active pain above 3 on a 0–10 scale

Uncontrolled hypertension (≥160/100 mmHg)

Chronic kidney disease stage 4–5 (filtration rate <30 mL/min/1.73 m²) on a sodium-restricted regimen

Congestive heart failure, New York Heart Association Class III–IV, on sodium restriction

Key Interactions

Antihypertensive medication (amlodipine, lisinopril, losartan): Caution

Lithium and sodium-losing diuretics (furosemide, hydrochlorothiazide): Caution

Sodium-containing over-the-counter products: Monitor

Electrolyte and sodium-bicarbonate supplements: Additive; monitor

Glutamine supplements: Additive; monitor

5'-ribonucleotide flavour enhancers: Potentiating; monitor

Other dietary free-glutamate sources: Additive; monitor

Salt-substitute and low-sodium dietary programmes: Complementary; monitor

Risk & Side Effects

High: Symptom complex after large doses without food

Medium: Higher blood pressure with high habitual intake; snoring and sleep-disordered breathing in lean adults; aggravation of chronic myofascial pain

Low: Weight gain, overweight and metabolic syndrome; asthma symptoms in sensitized individuals

Speculative: Gut microbiome shifts; excitotoxic neuronal injury; reproductive and endocrine disruption

Monitoring

Marker	Target	Why
Seated blood pressure (home average)	<120/75 mmHg	Primary outcome the intervention is meant to improve and the risk it may worsen
24-hour urinary sodium	<2,300 mg/day; <1,500 mg/day where pressure is elevated	Objective record of whether salt was actually displaced rather than added to
Fasting glucose	75–86 mg/dL	Tests the post-meal glycaemic claim over the longer term
Glycated hemoglobin (HbA1c)	4.8–5.3%	Confirms that any acute glycaemic effect translates into sustained control
Waist circumference	<94 cm men, <80 cm women	Tracks the adiposity signal reported in cohort studies
Hemoglobin	13.5–15.0 g/dL men, 12.5–14.5 g/dL women	Relevant where low appetite or anemia motivated the change
High-sensitivity C-reactive protein (hs-CRP)	<1.0 mg/L	Inflammation is the proposed condition under which excitotoxic concerns would apply
Apnea-hypopnea index	No established target for this intervention; track change from the individual's own baseline	Follows the sleep-breathing association seen in lean adults

Cadence: Home blood pressure twice daily for the first eight weeks after an increase, then quarterly; urinary sodium, fasting glucose, glycated hemoglobin and body composition at 3 months, then every 6–12 months; symptom diary continuously through any elimination and rechallenge sequence.

Qualitative Assessment

Headache frequency and intensity, recorded daily rather than recalled
Perceived saltiness of habitual foods, which typically rises as salt preference readjusts
Appetite and meal satisfaction, particularly where low intake prompted the change
Facial flushing, tingling or muscle tightness within two hours of a savoury meal
Snoring reports from a bed partner, and daytime sleepiness
Jaw, neck and generalised muscle pain in those with a pain condition

Glutamate for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment